Cutaneous desmop astic melanoma - Reappraisal of morphologic heterogeneity and prognostic factors

被引:150
作者
Busam, KJ
Mujumdar, U
Hummer, AJ
Nobrega, J
Hawkins, WG
Coit, DG
Brady, MS
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
关键词
desmoplastic; melanoma; prognostic factors;
D O I
10.1097/01.pas.0000141391.91677.a4
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Desmoplastic melanoma (DM) is a variant of melanoma, which may be confused with nonmelanocytic benign or malignant spindle cell proliferations. The histologic hallmark of DM is the presence of fusiform melanocytes dispersed in a prominent collagenous stroma. Phenotypic heterogeneity of DM is underrecognized. Desmoplasia may be prominent throughout the entire tumor ("pure" DM) or represent a portion of an otherwise nondesmoplastic melanoma ("combined" DM). We reviewed melanomas with desmoplasia from 92 patients seen at a single institution between 1980 and 2002. Fifty-five of the tumors were pure DM. Thirty-seven were classified as combined. Mean follow-up of patients was 46 months for those alive at the last follow-up. Univariate analysis of clinical and pathologic parameters revealed four significant variables for disease-free survival: Clark level (IV vs. V; P = 0.005), DM subtype (pure vs. combined; P = 0.01), tumor mitotic rate (<1, 1-4, >4 mitoses/mm(2); P = 0.01), and tumor thickness (<1 mm, 1-4 mm, >4 mm; P = 0.02). Only histologic subtype (P = 0.02) and Clark level (P = 0.05) were independently significant by Cox regression analysis. Our results indicate that distinguishing pure from combined forms of DM is clinically relevant for prognosis (pure forms being associated with longer disease-specific survival). Failure to make this distinction may account for conflicting reports in the literature on the biologic behavior and prognosis of DM.
引用
收藏
页码:1518 / 1525
页数:8
相关论文
共 35 条
[1]   DESMOPLASTIC MALIGNANT-MELANOMA - A CLINICOPATHOLOGICAL STUDY OF 25 CASES [J].
ANSTEY, A ;
MCKEE, P ;
JONES, EW .
BRITISH JOURNAL OF DERMATOLOGY, 1993, 129 (04) :359-371
[2]  
Arbiser ZK, 2001, AM J CLIN PATHOL, V116, P473
[3]  
BAER SC, 1995, CANCER, V76, P2242, DOI 10.1002/1097-0142(19951201)76:11<2242::AID-CNCR2820761110>3.0.CO
[4]  
2-I
[5]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[6]  
BEENKEN S, 1989, ARCH OTOLARYNGOL, V115, P374
[7]   Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma [J].
Busam, KJ ;
Iversen, K ;
Coplan, KC ;
Jungbluth, AA .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (02) :197-204
[8]  
CARLSON JA, 1995, CANCER, V75, P478, DOI 10.1002/1097-0142(19950115)75:2<478::AID-CNCR2820750211>3.0.CO
[9]  
2-O
[10]  
CONLEY J, 1971, CANCER, V28, P914, DOI 10.1002/1097-0142(1971)28:4<914::AID-CNCR2820280415>3.0.CO